2013 Update of the American Society of Clinical Oncology/College of American Pathologists Guideline for human epidermal growth factor receptor 2 testing: Impact on immunohistochemistry-negative breast cancers
ALGORITHM;
BREAST CANCER;
CANCER SCREENING;
FLUORESCENCE IN SITU HYBRIDIZATION;
HUMAN;
IMMUNOHISTOCHEMISTRY;
LETTER;
MEDICAL SOCIETY;
PATHOLOGIST;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update
Wolff AC, Hammond ME, Hicks DG, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997-4013, 2013
HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: Impact on selecting patients for herceptin therapy
Brunelli M, Manfrin E, Martignoni G, et al: HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: Impact on selecting patients for herceptin therapy. Am J Clin Pathol 129:907-911, 2008
Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: A study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and interobserver variation
Atkinson R, Mollerup J, Laenkholm AV, et al: Effects of the change in cutoff values for human epidermal growth factor receptor 2 status by immunohistochemistry and fluorescence in situ hybridization: A study comparing conventional brightfield microscopy, image analysis-assisted microscopy, and interobserver variation. Arch Pathol Lab Med 135:1010-1016, 2011
A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: Impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria
Schalper KA, Kumar S, Hui P, et al: A retrospective population-based comparison of HER2 immunohistochemistry and fluorescence in situ hybridization in breast carcinomas: Impact of 2007 American Society of Clinical Oncology/College of American Pathologists criteria. Arch Pathol Lab Med 138:213-219, 2014
Distinguishing score 0 from score 1+ in HER2 immunohistochemistry- negative breast cancer: Clinical and pathobiological relevance
Lambein K, Van Bockstal M, Vandemaele L, et al: Distinguishing score 0 from score 1+ in HER2 immunohistochemistry-negative breast cancer: Clinical and pathobiological relevance. Am J Clin Pathol 140:561-566, 2013
